Factor VIII gene therapy - Novartis
Alternative Names: Haemophilia A gene therapy - NovartisLatest Information Update: 24 Oct 2021
At a glance
- Originator Novartis
- Class Blood coagulation factors; Coagulants
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haemophilia A
Most Recent Events
- 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
- 17 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the Haematological disorders therapeutic trials section
- 28 Oct 2003 A clinical study has been added to the adverse events and pharmacokinetic sections